摘要
目的:评价血必净注射液对慢性阻塞性肺疾病急性加重(AECOPD)患者炎症指标及免疫功能的影响。方法:计算机检索PubMed,Cochrane图书馆,Embase,Wed of Science,CBM,CNKI,VIP和万方数据在线知识服务平台,所有检索时间截止到2020年2月。由两名研究者独立进行文献筛选及质量评价后提取相关数据,采用RevMan5.3软件进行Meta分析。结果:共纳入21篇随机对照试验(RCT),1 618例患者。Meta分析结果显示,血必净注射液辅助治疗在总有效率[相对危险度(RR)=1.20,95%置信区间(CI)(1.14,1.27),P<0.000 01],C-反应蛋白(CRP)[标准化均数差(SMD)=-1.58,95%CI(-1.98,-1.19),P<0.000 01],白细胞总数(WBC)[均数差(MD)=-1.44,95%CI(-1.84,-1.04),P<0.000 01],降钙素原(PCT)[SMD=-0.57,95%CI(-0.74,-0.41),P<0.000 01],白细胞介素-6(IL-6)[SMD=-1.51,95%CI(-2.07,-0.96),P<0.000 01],中性粒细胞百分比(N%)[MD=-5.35,95%CI(-7.13,-3.58),P<0.000 01],肿瘤坏死因子-α(TNF-α)[SMD=-1.52,95%CI(-2.23,-0.81),P<0.000 1]显著优于对照组,并在调节细胞免疫紊乱方面具有积极作用。结论:血必净注射液联合常规治疗可以调节AECOPD患者的免疫功能,降低炎症指标、中性粒细胞及CD8+T细胞的数量从而改善小气道微循环以促进炎症的吸收抑制本病进展,具有良好的安全性。
Objective: To evaluate the effect of Xuebijing injection on inflammatory indexes and immune function in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method: PubMed,Cochrane Library,Embase,Wed of Science,CBM,CNKI,VIP and Wanfang Data Online Knowledge service platform were searched by computer,all of which were up to February 2020. After literature screening and quality evaluation by two researchers independently,relevant data were extracted and Metaanalysis was carried out by RevMan 5.3 software. Result:A total of 21 randomized controlled trials(RCT)were included,involving 1 618 patients. The results of Meta-analysis showed,Xuebijing injection adjuvant therapy was significantly better than the control group in total effective rate[relative risk(RR)=1.20,95% confidence interval(CI)(1.14,1.27),P<0.000 01],C-reactive protein(CRP)[standard mean difference(SMD)=-1.58,95%CI(-1.98,-1.19),P<0.000 01],total white blood cell(WBC)[mean difference(MD)=-1.44,95% CI(-1.84,-1.04),P<0.000 01],procalcitonin(PCT)[SMD=-0.57,95% CI(-0.74,-0.41),P<0.000 01],interleukin-6(IL-6)[SMD=-1.51,95% CI(-2.07,-0.96),P<0.000 01],percentage of neutrophils(N%)[MD=-5.35,95% CI(-7.13,-3.58),P<0.000 01],and tumor necrosis factor-α(TNF-α)[SMD=-1.52,95% CI(-2.23,-0.81),P<0.000 1],and had positive effects in regulating cellular immune disorders. Conclusion:Xuebijing injection combined with routine treatment can improve the immune function of AECOPD patients,reduce the number of inflammatory markers,neutrophils and CD8+T cells,thus modulating the small airway microcirculation to promote inflammatory absorption and inhibit the progression of the disease,with high safety.
作者
李叶卉
朱文
周贤梅
LI Ye-hui;ZHU Wen;ZHOU Xian-mei(Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210009,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2021年第8期188-195,共8页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金项目(81673936)。
关键词
慢性阻塞性肺疾病
急性加重
血必净注射液
随机对照试验
META分析
chronic obstructive pulmonary disease
acute exacerbation
Xuebijing injection
randomized controlled trial
Meta-analysis
